PT - JOURNAL ARTICLE AU - T Berger Gillam AU - J Cole AU - K Gharbi AU - E Angiolini AU - T O Barker AU - P Bickerton AU - T Brabbs AU - J S Chin AU - E Coen AU - Sarah Cossey AU - R P Davey AU - R Davidson AU - A Durrant AU - D Edwards AU - N Hall AU - S Henderson AU - M Hitchcock AU - N Irish AU - J Lipscombe AU - G Jones AU - G Parr AU - S Rushworth AU - N Shearer AU - R Smith AU - N Steel TI - Norwich COVID-19 Testing Initiative pilot: evaluating the feasibility of asymptomatic testing on a university campus AID - 10.1101/2020.09.22.20199455 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.22.20199455 4099 - http://medrxiv.org/content/early/2020/10/01/2020.09.22.20199455.short 4100 - http://medrxiv.org/content/early/2020/10/01/2020.09.22.20199455.full AB - Background There is a high prevalence of COVID-19 in university-age students, who are returning to campuses. There is little evidence regarding the feasibility of universal, asymptomatic testing to help control outbreaks in this population. This study aimed to pilot mass COVID-19 testing on a university research park, to assess the feasibility and acceptability of scaling up testing to all staff and students.Methods This was a cross-sectional feasibility study on a university research park in the East of England. All staff and students (5,625) were eligible to participate. All participants were offered 4 PCR swabs, which they self-administered over two weeks. Outcome measures included: uptake; drop-out rate; positivity rates; participant acceptability measures; laboratory processing measures; data collection and management measures.Results 798 (76%) of 1053 who registered provided at least one swab. 687 (86%) provided all four. 792 (99%) of 798 who submitted at least one swab had all negative results. 6 participants had one inconclusive result. There were no positive results. 458 (57%) of 798 participants responded to a post-testing survey, demonstrating a mean acceptability score of 4.51/5, with 5 being the most positive.Conclusions Repeated self-testing for COVID-19 using PCR is feasible and acceptable to a university population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementProject funding was provided by the UK Research and Innovation (UKRI) Biotechnology and Biological Sciences Research Council (BBSRC) Core Capability Grant BBS/E/T/000PR9816, Quadram Institute, John Innes Centre, and the University of East Anglia, generously supported by local charities and philanthropists. The CyVerse UK cloud is funded by the BBSRC National Capability award to EI BBS/E/T/000PR9814.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UEA ethics committee no. 2019/20-140All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during during the current study are available from the corresponding author on reasonable request.